What Is Psychedelic-Assisted Therapy Best For? A Condition-by-Condition Guide
A research-backed guide to which mental health conditions psychedelic-assisted therapy works best for — from treatment-resistant depression and PTSD to end-of-life anxiety and addiction.
Psychedelic-assisted therapy has moved from the cultural fringe to peer-reviewed journals, clinical trials, and licensed service centers in two U.S. states. Ketamine is FDA-approved and available nationwide. Psilocybin is legal in Oregon and Colorado. MDMA-assisted therapy for PTSD has completed large Phase 3 trials. The science is real, the interest is enormous — and one question keeps coming up: Is this actually right for me?
The honest answer is: it depends entirely on what you are dealing with. Psychedelic-assisted therapy is not a universal treatment. For some conditions, the evidence is genuinely strong. For others, it remains early and speculative. This guide lays out which conditions have the best clinical support, which are still under active investigation, and who may not be a good fit at all.
30%
What Counts as Psychedelic-Assisted Therapy?
Before evaluating evidence by condition, a brief map of the landscape:
- Ketamine — The most widely available option. Used off-label at ketamine clinics nationwide and delivered as the FDA-approved nasal spray esketamine (Spravato) for treatment-resistant depression. Backed by the largest body of real-world data.
- Psilocybin — The psychoactive compound in certain mushrooms. Legal through licensed service centers in Oregon and Colorado; available through clinical trials elsewhere. Multiple high-quality randomized controlled trials published.
- MDMA — Completed Phase 3 trials for PTSD with compelling results; received a Complete Response Letter from the FDA in 2024 and remains in regulatory review. Not yet commercially available.
- Other compounds — LSD, ibogaine, DMT, and others are being studied but are in early-phase research without established clinical pathways in the U.S.
This guide focuses on ketamine and psilocybin — the treatments you can access now — while covering MDMA where the evidence is strong and the regulatory picture may shift.
Where Psychedelic-Assisted Therapy Works Best
1. Treatment-Resistant Depression
This is where the evidence is strongest, and where psychedelic-assisted therapy has the best argument for being not just a treatment but potentially the best option for a specific group.
Treatment-resistant depression is typically defined as depression that has not responded to at least two adequate antidepressant trials. Approximately 30 percent of people with major depressive disorder fall into this category — an estimated 17 million Americans. For this group, conventional options are limited and often unsatisfying.
Ketamine works rapidly (sometimes within hours), which makes it valuable for acute suicidal ideation as well as chronic depression. A landmark NIMH-funded meta-analysis found that 67 percent of patients with treatment-resistant depression experienced a meaningful response after a single infusion. A full course of six infusions produces response rates of 50 to 70 percent.
Psilocybin has demonstrated remarkable results in multiple randomized controlled trials. A 2022 trial published in The New England Journal of Medicine comparing psilocybin to the SSRI escitalopram found psilocybin non-inferior on the primary measure and superior on several secondary measures of well-being. An Imperial College London trial found that two doses of psilocybin with psychological support produced sustained reductions in depression scores at six-month follow-up in a treatment-resistant group.
67%
Best for: People with documented treatment-resistant depression who have tried multiple medications without adequate benefit, as well as those experiencing acute suicidal ideation where rapid response is critical (ketamine specifically).
2. Post-Traumatic Stress Disorder (PTSD)
PTSD represents the most compelling case for MDMA-assisted therapy, with results from Phase 3 trials that few psychiatric treatments in history have matched.
In the MAPS-sponsored Phase 3 trial (Mitchell et al., Nature Medicine, 2021), 67 percent of participants who received MDMA-assisted therapy no longer met diagnostic criteria for PTSD after treatment, compared to 32 percent in the placebo group. A second Phase 3 trial replicated these results. The average patient entered treatment with severe PTSD — much of it chronic and treatment-resistant — and left with dramatic reductions in hyperarousal, avoidance, and intrusive symptoms.
The proposed mechanism is important: MDMA appears to reduce activity in the amygdala (the brain's fear-processing center) while increasing activity in prefrontal cortex areas responsible for emotional regulation. This may create a neurological window in which traumatic memories can be processed without triggering overwhelming emotional flooding — something that can derail traditional trauma therapies in severely traumatized patients.
Because MDMA-assisted therapy is not yet commercially available, people with PTSD currently have two routes: clinical trial enrollment (which provides treatment at no cost) or one of the evidence-based alternatives like EMDR or Cognitive Processing Therapy.
Best for: Severe, treatment-resistant PTSD, particularly in cases where emotional flooding has interfered with traditional trauma processing approaches.
3. End-of-Life Existential Anxiety
For people facing a terminal diagnosis, anxiety and existential distress can be profound and under-treated. Conventional anxiolytics and antidepressants work, but they blunt affect rather than facilitate the deeper psychological work many people want at the end of life.
Psilocybin therapy has shown particularly striking results in this population. Landmark studies by Roland Griffiths at Johns Hopkins (2016) and Stephen Ross at NYU (2016) both found that a single dose of psilocybin with psychological support produced significant, lasting reductions in anxiety and depression in patients with life-threatening cancer — with effects persisting at six-month follow-up. Approximately 80 percent of participants reported the experience as among the most personally meaningful of their lives.
The mechanism appears to involve mystical-type experiences that shift patients' relationship to death, isolation, and meaning — outcomes that are difficult or impossible to replicate through conventional psychotherapy alone.
80%
Best for: Terminal illness with significant existential distress, anxiety, or depression; patients who want to engage meaningfully with the psychological dimensions of dying.
4. Alcohol Use Disorder and Other Addictions
Addiction represents a third area where psychedelic-assisted therapy has moved beyond anecdote into rigorous clinical testing.
A 2022 randomized controlled trial in The New England Journal of Medicine (Bogenschutz et al.) found that psilocybin-assisted treatment significantly reduced heavy drinking days compared to active placebo. At the eight-month follow-up, participants who received psilocybin had more than double the rate of abstinence compared to controls.
Separate Johns Hopkins research has found psilocybin effective for nicotine addiction, with 80 percent of participants abstinent at six-month follow-up — a rate dramatically higher than what standard cessation treatments typically produce.
Ibogaine, a compound derived from the African iboga plant, has shown remarkable effectiveness for opioid use disorder in research settings, but it carries significant cardiovascular risks and is not approved or widely available in the U.S. Research continues, particularly following the opening of regulated ibogaine clinics in Mexico and other countries.
Best for: Alcohol use disorder where conventional treatment and motivational approaches have not produced lasting change; nicotine dependence resistant to pharmacotherapy and behavioral approaches.
Who Is NOT a Good Candidate
Psychedelic-assisted therapy is not appropriate for everyone, and honest evaluation of exclusion criteria is essential. You may not be a good candidate if you:
- Have a personal or family history of psychosis or schizophrenia — psychedelic compounds can trigger or exacerbate psychotic episodes in vulnerable individuals.
- Have active bipolar I disorder — the manic switch risk is not well-characterized and most protocols exclude bipolar I patients.
- Take lithium or MAOIs — interactions with certain psychedelics can be dangerous.
- Are pregnant or breastfeeding — there is insufficient safety data.
- Have uncontrolled cardiovascular disease — ketamine in particular elevates blood pressure and heart rate.
- Are currently in a mental health crisis — psychedelic experiences are intense and require psychological stability to navigate safely; active suicidal crisis (without access to the supervised clinical setting) or acute psychiatric decompensation are contraindications.
How to Know If Psychedelic-Assisted Therapy Might Be Right for You
If you are considering psychedelic-assisted therapy, a structured self-assessment helps clarify fit:
-
Document your treatment history. Have you tried conventional approaches — therapy, medication, or both — for your primary condition without adequate benefit? Psychedelic therapies are best positioned as options after first-line treatments, not instead of them.
-
Identify your specific condition and goal. The evidence supports specific applications. If your condition is in the strong-evidence category (treatment-resistant depression, PTSD, end-of-life anxiety, addiction), the case for exploration is stronger than if you have generalized anxiety that has never been treated.
-
Consult a psychiatrist, not just a ketamine clinic. A board-certified psychiatrist who specializes in this area can evaluate your full history, identify contraindications, help you navigate esketamine insurance coverage if applicable, and point you toward clinical trials if appropriate.
-
Research access honestly. Esketamine is widely covered by insurance for qualifying diagnoses. IV ketamine is largely out of pocket. Psilocybin services require travel to Oregon or Colorado and are entirely self-pay. MDMA-assisted therapy requires clinical trial enrollment. Know what you can access before you commit emotionally to one path.
For related reading on the full treatment landscape for depression, the evidence behind EMDR for trauma, or the costs involved in psychedelic treatment programs, see the linked guides below.
Frequently Asked Questions
The current evidence base is not strong enough to recommend psychedelic-assisted therapy for general anxiety or moderate stress that has not been treatment-resistant. Standard evidence-based options like cognitive behavioral therapy and SSRIs are the first-line approach for most anxiety presentations. Psychedelic therapies are best reserved for cases where conventional treatments have failed or for specific high-evidence applications like end-of-life existential distress.
Early research is promising. A small open-label trial at Yale (Goodwin et al., 2022) found significant reductions in OCD symptoms following psilocybin administration. However, the evidence is preliminary compared to the robust data for depression and end-of-life anxiety. Exposure and Response Prevention (ERP) remains the gold-standard first-line treatment for OCD. Psilocybin for OCD is best pursued through clinical trials at this stage.
Yes, in certain circumstances. Psychedelic experiences can be psychologically intense, and for people with undetected vulnerabilities — particularly those with a personal or family history of psychosis or bipolar I disorder — they can trigger psychiatric decompensation. This is why rigorous screening is essential. In properly screened and supported participants in clinical trials, serious adverse events are rare, but self-directed use outside clinical supervision carries substantially higher risk.
For ketamine, the standard initial course is six infusions over two to three weeks, with many patients requiring periodic maintenance infusions every four to eight weeks. For psilocybin, clinical trials have used one to two sessions with significant preparatory and integration therapy surrounding each session. End-of-life anxiety studies have shown remarkable results from a single psilocybin dose embedded in a full therapeutic program.
Preliminary, but growing. A small open-label trial of psilocybin for anorexia nervosa at Johns Hopkins showed promising results, with participants reporting meaningful shifts in their relationship to food and body image. Larger randomized trials are underway. Eating disorder treatment remains an area where conventional evidence-based approaches — including family-based treatment and CBT-E — should be the first-line choice, with psychedelic-assisted approaches pursued through clinical trials in treatment-resistant cases.
Several strong options exist. EMDR, Cognitive Processing Therapy, and Prolonged Exposure are all evidence-based, widely available, and often covered by insurance. If these have been tried without sufficient benefit, enrollment in a clinical trial for MDMA-assisted therapy is worth pursuing — participants receive treatment at no cost. Ketamine has also shown some benefit for PTSD symptoms, particularly hyperarousal, and is available now through licensed providers.
For psilocybin, access currently requires travel to a licensed service center in Oregon or Colorado, or enrollment in a clinical trial. Ketamine and esketamine are available nationwide through licensed providers and prescribers. MDMA-assisted therapy is accessible only through clinical trials regardless of location. As more states consider decriminalization and regulation frameworks, legal access will likely expand — but today, geography matters significantly for psilocybin access.
Enormously. Clinical research consistently shows that psychedelic-assisted therapy is a combined intervention — the drug experience plus structured psychological support before, during, and after the session. Preparation and integration therapy help patients approach the experience with intention and translate insights into lasting behavioral change. Studies suggest that the quality of the therapeutic relationship and the presence of trained support during the session are independent predictors of outcome, separate from the drug's direct effects.
Explore Whether Psychedelic Therapy Is Right for You
Understanding which conditions benefit most is the first step. Learn how psychedelic-assisted therapy compares to other evidence-based options and what questions to ask a qualified provider.
Read the Full Psychedelic Therapy Overview